Home > News > Nanosphere Eyes $100M IPO
August 13th, 2007
Nanosphere Eyes $100M IPO
Abstract:
Personalized-medicine startup Nanosphere filed for a $100 million IPO Monday, but an analyst said the move could be a prelude to a merger with one of its larger rivals.
Nanosphere, based in Northbrook, Illinois, makes a system to perform molecular diagnostic tests. Earlier this year Nanosphere applied for U.S. Food and Drug Administration approval of tests to gauge a person's risk of blood clots and how a patient metabolizes the anti-blood clot medicine warfarin, sold under the brand name Coumadin.
The company also is developing tests for cancer, cystic fibrosis gene mutation, herpes viral infection, and cardiovascular disease risk and diagnosis.
Source:
redherring.com
Bookmark:
| Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Rice membrane extracts lithium from brines with greater speed, less waste October 3rd, 2025
Researchers develop molecular qubits that communicate at telecom frequencies October 3rd, 2025
Next-generation quantum communication October 3rd, 2025
"Nanoreactor" cage uses visible light for catalytic and ultra-selective cross-cycloadditions October 3rd, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||